Nebojsa Janjic

USPTO Granted Patents = 70 (Patent Applications = 16)

CIPO Patents = 7 (Patent Applications = 4)

EPO Patents = 16 (Patent Applications = 24)

Average Co-Inventor Count = 3.1

ph-index = 20

Forward Citations = 1,664(Granted Patents)

Inventors with similar research interests:

Location History:

Lafayette, CO (US) (1997 - 2001)
Boulder, CO (US) (1995 - 2023)

Company Filing History:

24 out of 75

Somalogic, Incorporated

patents

17 out of 131

Nexstar Pharmaceuticals, Inc.

patents

17 out of 919

Gilead Sciences, Inc.

Somalogic Operating Co., Inc.

patents

6. 1 out of 2

Nexstar Pharmaceuticlas, Inc.

Otsuka Pharmaceutical Company, Limited

patents

11. 1 out of 1,376

University of Colorado

patents

12. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2024

Loading Chart...

70 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180482 - Oligonucleotides comprising modified nucleosides (2024-12-31),

2. 11578330 - Oligonucleotides comprising modified nucleosides (2023-02-14),

3. 11535852 - Nucleic acid compounds for binding growth differentiation factor 11 (2022-12-27),

4. 11221340 - Lung cancer biomarkers and uses thereof (2022-01-11),

5. 11208663 - Post-selex modification methods (2021-12-28),

6. 10927380 - Oligonucleotides comprising modified nucleosides (2021-02-23),

7. 10808251 - Nucleic acid compounds for binding growth differentiation factor 11 (2020-10-20),

8. 10544419 - PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders (2020-01-28),

9. 10538771 - Compositions and methods for detecting microorganisms (2020-01-21),

10. 10526663 - Method of detecting a microorganism in a sample by a fluorescence based detection method (2020-01-07),

11. 10408847 - Tuberculosis biomarkers and uses thereof (2019-09-10),

12. 10392621 - Multiaptamer target detection (2019-08-27),

13. 10370669 - Nucleic acid compounds for binding growth differentiation factor 8 (2019-08-06),

14. 10239908 - Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto (2019-03-26),

15. 10221421 - Post-selec modification methods (2019-03-05),

Title: The Innovative Contributions of Nebojsa Janjic

Introduction: Nebojsa Janjic, a prominent inventor based in Boulder, Colorado, is recognized for his groundbreaking work in the field of oligonucleotide chemistry. With an impressive portfolio of 70 patents to his name, Janjic continues to drive innovations that have significant implications for various scientific and medical applications.

Latest Patents: Among his notable contributions are his latest patents that focus on oligonucleotides comprising modified nucleosides. These polynucleotides, specifically aptamers, include at least two different 5-position modified pyrimidines, enhancing their versatility and effectiveness. Janjic's methods of selecting and using such polynucleotides offer novel approaches for applications in diagnostics and therapeutics.

Career Highlights: Over his distinguished career, Janjic has made significant strides in biochemistry and molecular biology. His tenure at companies such as Somalogic, Incorporated and Nexstar Pharmaceuticals, Inc. has enabled him to translate his innovative ideas into tangible advancements in health and medicine.

Collaborations: Throughout his career, Janjic has collaborated with several esteemed professionals in his field. Notable coworkers include Larry M. Gold and Urs Ochsner, both of whom share his commitment to advancing scientific understanding and application in their respective areas of expertise.

Conclusion: Nebojsa Janjic remains a key figure in the scientific community, continually pushing the boundaries of innovation through his patents and collaborations. His work not only exemplifies the spirit of invention but also fosters advancements that can lead to significant improvements in healthcare and beyond.

This text is generated by artificial intelligence and may not be accurate.